First National Trust Co Has $357,000 Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

First National Trust Co cut its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 25.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 600 shares of the biotechnology company’s stock after selling 200 shares during the period. First National Trust Co’s holdings in Axon Enterprise were worth $357,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of AXON. Public Sector Pension Investment Board increased its holdings in Axon Enterprise by 19.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company’s stock valued at $1,240,000 after purchasing an additional 500 shares in the last quarter. CIBC Asset Management Inc increased its holdings in Axon Enterprise by 9.2% during the 3rd quarter. CIBC Asset Management Inc now owns 10,578 shares of the biotechnology company’s stock valued at $4,227,000 after purchasing an additional 895 shares in the last quarter. Soros Capital Management LLC acquired a new stake in Axon Enterprise during the 3rd quarter valued at $630,000. Friedenthal Financial increased its holdings in Axon Enterprise by 961.7% during the 4th quarter. Friedenthal Financial now owns 1,359 shares of the biotechnology company’s stock valued at $808,000 after purchasing an additional 1,231 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in Axon Enterprise by 33.1% during the 3rd quarter. Principal Financial Group Inc. now owns 136,302 shares of the biotechnology company’s stock valued at $54,466,000 after purchasing an additional 33,869 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $639.69, for a total transaction of $639,690.00. Following the transaction, the director now directly owns 24,259 shares in the company, valued at approximately $15,518,239.71. The trade was a 3.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the completion of the sale, the director now owns 6,929 shares of the company’s stock, valued at $4,185,601.03. This trade represents a 6.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,146 shares of company stock valued at $3,262,847 in the last quarter. Company insiders own 6.10% of the company’s stock.

Axon Enterprise Stock Up 4.1 %

Shares of NASDAQ AXON opened at $556.26 on Friday. The firm has a 50 day moving average price of $593.42 and a 200 day moving average price of $535.46. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The stock has a market cap of $42.62 billion, a P/E ratio of 143.74, a P/E/G ratio of 5.17 and a beta of 1.12. Axon Enterprise, Inc. has a 52-week low of $273.52 and a 52-week high of $715.99.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of recent analyst reports. The Goldman Sachs Group raised their price target on Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a report on Monday, January 27th. Craig Hallum lowered Axon Enterprise from a “buy” rating to a “cautious” rating in a research report on Monday, March 10th. TD Cowen assumed coverage on Axon Enterprise in a research report on Wednesday, January 8th. They issued a “buy” rating and a $700.00 price objective on the stock. Robert W. Baird increased their price objective on Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a research report on Friday, December 6th. Finally, JMP Securities reiterated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $604.67.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.